Skip to main content
QTRX
NASDAQ Industrial Applications And Services

Quanterix Slashes 2026 Revenue Outlook, Pushes Cash Breakeven to 2027; Q2 Revenue Misses

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.68
Mkt Cap
$189.837M
52W Low
$2.395
52W High
$8.77
52W Position info
12% above low
Off High info
69% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

QTRX is trading near its 52-week low of $2.395 (12% above the low).

Summary

Quanterix missed Q2 revenue expectations, cut its full-year 2026 revenue guidance by about 15%, and pushed cash flow breakeven to 2027. A $26.9 million goodwill impairment and a new Chief Commercial Officer appointment rounded out a challenging quarter.


Key Events · Earnings and Guidance · QTRX

  • Q2 Revenue Misses Expectations

    Revenue of $32.9M grew 34% YoY but fell short of internal targets due to commercial execution challenges and market softness.

  • Full-Year Guidance Slashed

    2026 revenue guidance cut to $142–148M from $169–174M; adjusted gross margin now 48–50% vs. 49–53% prior.

  • Cash Breakeven Delayed to 2027

    Cash flow breakeven pushed from H2 2026 to 2027; year-end cash balance now expected at ~$80M, down from $100M.

  • $26.9M Goodwill Impairment

    Non-cash goodwill impairment charge related to the Akoya acquisition, reflecting recent business circumstances.


Analysis · QTRX · Industrial Applications And Services

Quanterix reported Q2 revenue of $32.9 million, up 34% year-over-year but well short of expectations, and slashed its full-year 2026 revenue guidance to $142–148 million from $169–174 million. The company also pushed its cash flow breakeven target to 2027 from the second half of 2026 and now expects to exit the year with about $80 million in cash, down from $100 million previously. A $26.9 million goodwill impairment tied to the Akoya acquisition further weighed on GAAP results. On the operational side, the appointment of Jim Gute as Chief Commercial Officer signals a push to fix commercial execution, but the guidance cut and delayed profitability timeline are the dominant headlines.

How filings like this one have moved

In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QTRX was trading at $2.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $189.8M. The 52-week trading range was $2.40 to $8.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QTRX - Latest Insights

QTRX
Aug 10, 2026, 8:34 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.58
Real-time Price: $3.65 info
Change: +$1.07 (+41%) info
Market Cap: $172.147M info
QTRX
Aug 10, 2026, 8:12 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $2.71
Real-time Price: $3.65 info
Change: +$0.940 (+35%) info
Market Cap: $172.147M info
QTRX
Jun 10, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.07
Real-time Price: $3.65 info
Change: +$0.580 (+19%) info
Market Cap: $172.147M info
QTRX
Jun 10, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.20
Real-time Price: $3.65 info
Change: +$0.450 (+14%) info
Market Cap: $172.147M info
QTRX
Jun 09, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.67
Real-time Price: $3.65 info
Change: -$0.020 (-0.54%) info
Market Cap: $172.147M info